KR910000172A - 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질길란텐 - Google Patents

남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질길란텐 Download PDF

Info

Publication number
KR910000172A
KR910000172A KR1019900008918A KR900008918A KR910000172A KR 910000172 A KR910000172 A KR 910000172A KR 1019900008918 A KR1019900008918 A KR 1019900008918A KR 900008918 A KR900008918 A KR 900008918A KR 910000172 A KR910000172 A KR 910000172A
Authority
KR
South Korea
Prior art keywords
patient
hementeria
leech
melanoma
giuliani
Prior art date
Application number
KR1019900008918A
Other languages
English (en)
Other versions
KR0185973B1 (ko
Inventor
더글라스 카딘 알란
프래새드 선카라 세이
Original Assignee
게리 디.스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디.스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 게리 디.스트리트
Publication of KR910000172A publication Critical patent/KR910000172A/ko
Application granted granted Critical
Publication of KR0185973B1 publication Critical patent/KR0185973B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/856—Snakes; venom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds
    • Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Road Paving Structures (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음

Description

남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질길란텐
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 에이취, 길리아니의 조타액선 추출물중의 FXa 억제활성을 나타내는 것이다.
제2도는 DEAE상의 음이온 교환에 의한 가용성 단백질 추출물 4㎎의 크로마토그래피를 나타내는 것이다.
제3도는 헤파린 아가로스 크로마토그래피에 의한 부분 정제된 FXa 억제제의 분획화를 나타내는 것이다.

Claims (8)

  1. 헤멘테리아 길리아니(Hementeria ghilianii)거머리의 타액으로부터 분리된 항전이 팩터(antimetastatic factor)또는 이의 약제학적으로 허용되는 염의 안전하고 종양 전이 형성을 억제하기에 충분한 양을 흑색종, 유방암, 폐암 또는 전립선암 환자에 투여함을 특징으로 하여, 종양전이의 형성을 억제하는 방법.
  2. 제1항에 있어서, 환자가 흑색종 또는 폐암 환자인 방법.
  3. 제1항에 있어서, 환자가 흑색종 환자인 방법.
  4. 제1항에 있어서, 환자가 폐암 환자인 방법.
  5. 제1항에 있어서, 항전이 팩터의 1일 투여 용량이 약 0.01 내지 약 2,000㎎/체중 ㎏인 방법.
  6. 제5항에 있어서, 1일 투여 용량이 1내지 약 200㎎/체중 ㎏인 방법.
  7. 제5항에 있어서, 종양성 물질을 제거하기 위한 외과적 방법을 위한 준비로 수행되는 방법.
  8. 제5항에 있어서, 화합물의 암의 검출 직후에 투여하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900008918A 1989-06-20 1990-06-18 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질 길란텐 KR0185973B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36861689A 1989-06-20 1989-06-20
US368616 1989-06-20
US43836589A 1989-12-14 1989-12-14
US438365 1989-12-14

Publications (2)

Publication Number Publication Date
KR910000172A true KR910000172A (ko) 1991-01-29
KR0185973B1 KR0185973B1 (ko) 1999-05-01

Family

ID=27004258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900008918A KR0185973B1 (ko) 1989-06-20 1990-06-18 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질 길란텐

Country Status (10)

Country Link
US (1) US5447911A (ko)
EP (1) EP0404055B1 (ko)
JP (1) JP2947882B2 (ko)
KR (1) KR0185973B1 (ko)
AT (1) ATE102041T1 (ko)
AU (1) AU624962B2 (ko)
DE (1) DE69006931T2 (ko)
DK (1) DK0404055T3 (ko)
ES (1) ES2052105T3 (ko)
IE (1) IE63540B1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047527A1 (en) * 1990-07-24 1992-01-25 Christopher Dunwiddie Method for administering a therapeutic anticoagulant
NZ270194A (en) * 1994-01-07 1996-05-28 Ciba Geigy Ag Hirustasin, a serine protease inhibitor from hirudo medicinalis
EP0662514A1 (en) * 1994-01-07 1995-07-12 Ciba-Geigy Ag Hirustasin, an antistasin type serine proteinase inhibitor from Hiruda
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
GB9930564D0 (en) 1999-12-23 2000-02-16 Evolutec Limited Screening method
US8004538B2 (en) 2007-09-21 2011-08-23 Global Oled Technology Llc Preferential tone scale for electronic displays
US8790711B2 (en) 2012-09-17 2014-07-29 Biopep Solutions, Inc. Treating diabetes with a whole, leech saliva extract
WO2015028919A1 (en) * 2013-08-29 2015-03-05 Daiichi Sankyo Company, Limited Agent for the treatment and prevention of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390630A (en) * 1980-10-28 1983-06-28 The Regents Of The University Of California Hementin--a fibrinolytic agent
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
IL83912A (en) * 1986-09-18 1993-05-13 Pennsylvania Hospital Protein having anticoagulant and antimetastatic properties
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii

Also Published As

Publication number Publication date
DK0404055T3 (da) 1994-03-28
EP0404055A1 (en) 1990-12-27
EP0404055B1 (en) 1994-03-02
DE69006931D1 (de) 1994-04-07
ES2052105T3 (es) 1994-07-01
AU5753890A (en) 1991-01-03
IE902212A1 (en) 1991-01-16
US5447911A (en) 1995-09-05
AU624962B2 (en) 1992-06-25
ATE102041T1 (de) 1994-03-15
IE63540B1 (en) 1995-05-17
JP2947882B2 (ja) 1999-09-13
KR0185973B1 (ko) 1999-05-01
JPH03128326A (ja) 1991-05-31
DE69006931T2 (de) 1994-08-18
IE902212L (en) 1990-12-20

Similar Documents

Publication Publication Date Title
EP0254067A3 (en) Composition for metastasis prevention
FR2416012A1 (fr) Derives de l'imidazole et medicament contenant ces substances
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
NZ295211A (en) Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids
GR78442B (ko)
KR910000172A (ko) 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질길란텐
HUP9900186A2 (hu) Lamellarin alkaloidok gyógyászati alkalmazása és az ezeket tartalmazó gyógyszerkészítmények
CA2028629A1 (en) Antiandrogenically-effective pharmaceutical compositions
SE8500996D0 (sv) Method of treatment
DE3479728D1 (en) Derivatives of thiophenesulfonamide, their preparation and pharmaceutical composition for the topical treatment of elevated intraocular pressure
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
EP0093497A3 (en) Anthelmintic treatment
DE3373099D1 (en) Extract of plants of the family of hypoxidaceae for treatment of cancer
JPS55113721A (en) Immunity regulator
IT8349055A0 (it) B-osso-l-carbammoil-pirrolpropionitrile, procedimento per la loro produzione, preparati farmaceutici con tenenti questi composti, nonche' il loro impiego terapeutico
JPS5612307A (en) External preparation
KR0177821B1 (en) Pharmaceutical compositions containing 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
BE899987A (fr) Nouvelles compositions pharmaceutiques antitumorales.
FR2417511A1 (fr) Derives de l'eburnamonine, leur preparation et medicaments contenant ces substances
JPS53127808A (en) Preparation of human albumin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031218

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee